Steroid implant for macular oedema

Ozurdex is an intravitreal implant containing 700 micograms of dexamethasone. It is indicated for the treatment of macular oedema following either branch retinal vein occlusion or central retinal vein occlusion. Treatment must be administered by an ophthalmologist.

Researchers tested Ozurdex in two double-blind, randomised trials in a total of 1267 patients. At 90 days after a single injection, the proportion of patients who had responded was significantly greater in the Ozurdex group than in the sham treatment group (21.8% vs 13.1%, p<0.001). Response was defined as an improvement of 15 letters or more in best corrected visual acuity.

Corticosteroids such as dexamethasone suppress the production of vascular endothelial growth factor, a cytokine that is involved in the development of macular oedema.

View Ozurdex drug record

Further information: Allergan

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Don't treat subclinical hypothyroidism, prescribers advised

Don't treat subclinical hypothyroidism, prescribers advised

GPs should monitor patients with subclinical hypothyroidism...

Refresh your knowledge on prescribing in pregnancy with MIMS Learning

Refresh your knowledge on prescribing in pregnancy with MIMS Learning

MIMS Learning is offering a new interactive module,...

Drug shortages - live tracker

Drug shortages - live tracker

Check on the latest drug supply issues with MIMS' shortages...

Antidiabetic Agents, Use in Renal Impairment

Antidiabetic Agents, Use in Renal Impairment

Dosing of diabetes drugs in patients with renal impairment.